Morgan Stanley Maintains Underweight on Integra Lifesciences, Raises Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Drew Ranieri maintains an Underweight rating on Integra Lifesciences (NASDAQ:IART) but raises the price target from $24 to $27.
July 15, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley analyst Drew Ranieri maintains an Underweight rating on Integra Lifesciences but raises the price target from $24 to $27.
The Underweight rating suggests a bearish outlook, but the raised price target indicates some positive expectations. The mixed signals are likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100